Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

Completed

Conditions: Migraine

Interventions: Other: Erenumab

First Posted Date: 2022-05-16

Last Posted Date: 2022-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 162

Registration Number: NCT05375097

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Sabatolimab
Drug: Magrolimab
Drug: Azacitidine

First Posted Date: 2022-05-10

Last Posted Date: 2024-04-11

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05367401

An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

Completed

Conditions: Plaque Psoriasis

Interventions: Other: Secukinumab

First Posted Date: 2022-05-10

Last Posted Date: 2022-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 767

Registration Number: NCT05368818

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)

Completed

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)

Interventions: Other: CAR-T
Other: Allo-HSCT cohort

First Posted Date: 2022-05-09

Last Posted Date: 2022-07-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 160602

Registration Number: NCT05366257

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

Recruiting

Conditions: Hypercholesterolemia

Interventions: Other: Inclisiran

First Posted Date: 2022-05-05

Last Posted Date: 2024-07-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2030

Registration Number: NCT05362903

Locations: 🇩🇪
Novartis Investigative Site, Zwiesel, Germany

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Phase 3

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Inclisiran sodium 300 mg

First Posted Date: 2022-05-04

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 600

Registration Number: NCT05360446

Locations: 🇺🇸
Heart Center Research Llc, Huntsville, Alabama, United States
🇺🇸
UC San Diego Health, La Jolla, California, United States
🇺🇸
Stanford Health Care, Stanford, California, United States

and more 30 locations

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small Cell Lung
Colorectal Tumors
Neoplasms, Colorectal
KRAS G12C Mutant Solid Tumors
Non-Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung
Colorectal Carcinoma
Nonsmall Cell Lung Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: JDQ443
Drug: Ribociclib
Drug: trametinib
Biological: cetuximab

First Posted Date: 2022-05-03

Last Posted Date: 2024-11-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 346

Registration Number: NCT05358249

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
NYU School of Medicine, New York, New York, United States

and more 1 locations

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Phase 3

Active, not recruiting

Conditions: Sjogren Syndrome

Interventions: Other: Placebo
Biological: VAY736

First Posted Date: 2022-04-27

Last Posted Date: 2024-10-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 276

Registration Number: NCT05350072

Locations: 🇺🇸
Altoona Center for Clin Res ., Duncansville, Pennsylvania, United States
🇺🇸
Medvin Clinical Research ., Van Nuys, California, United States
🇺🇸
West Broward Rheumatology Associates Inc, Tamarac, Florida, United States

and more 11 locations

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Phase 3

Active, not recruiting

Conditions: Sjogren Syndrome

Interventions: Biological: VAY736
Other: Placebo

First Posted Date: 2022-04-27

Last Posted Date: 2024-08-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 505

Registration Number: NCT05349214

Locations: 🇬🇧
Novartis Investigative Site, Swindon, United Kingdom
🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
Advanced Medical Research Medical Research, La Palma, California, United States

and more 21 locations

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Completed

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)

Interventions: Other: KYMRIAH
Other: YESCARTA

First Posted Date: 2022-04-27

Last Posted Date: 2022-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 273

Registration Number: NCT05349201

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy